The International Ki67 in Breast Cancer Working Group (IKWG) suggest that the use of Ki-67 IHC, as opposed to more expensive multi-gene assays, is adequate for determining prognosis for breast cancer patients with ER positive disease with very low (5%) or very high (≥30%) Ki-67 scores. Here, ESR1 is linked to breast carcinoma.